-
Purdue Pharma L.P. et al v. Teva Pharmaceuticals USA, Inc. DC CAFC
- 1:11-cv-02037
- S.D.N.Y.
- Judge: Sidney H. Stein
- Filed: 03/23/2011
- Closed: 01/14/2014
- Latest Docket Entry: 05/11/2016
- PACER
5
Plaintiffs
2
Defendants
1
Accused
Product
4
Patents-in-Suit
1,029
Days in
Litigation
-
Purdue Pharma L.P. et al v. Teva Pharmaceuticals USA, Inc. DC CAFC
- 1:11-cv-02037
- S.D.N.Y.
- Judge: Sidney H. Stein
- Filed: 03/23/2011
- Closed: 01/14/2014
- Latest Docket Entry: 05/11/2016
- PACER
Market Sector
Biotech and Pharma
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
30 |
Oxycodone salt prepared according to the process of claim 1.
|
Invalid
Entry 150 |
31 |
Oxycodone salt according to claim 30, wherein the oxycodone salt is oxycodone hydrochloride.
|
Invalid
Entry 150 |
32 |
Oxycodone salt according to claim 31 having less than about 25 ppm 14-hydroxycodeinone.
|
Invalid
Entry 150 |
33 |
Oxycodone salt according to claim 32 having less than about 15 ppm 14-hydroxycodeinone.
|
Invalid
Entry 150 |
76 |
Oxycodone salt prepared according to the process of claim 57.
|
Invalid
Entry 150 |
77 |
Oxycodone salt according to claim 76, wherein the oxycodone salt is oxycodone hydrochloride.
|
Invalid
Entry 150 |
78 |
Oxycodone salt according to claim 77 having less than about 25 ppm 14-hydroxycodeinone.
|
Invalid
Entry 150 |
79 |
Oxycodone salt according to claim 78 having less than about 15 ppm 14-hydroxycodeinone.
|
Invalid
Entry 150 |
Claim # | Claim Text | Outcome |
---|---|---|
3 |
An oral dosage form comprising: (i) from about 5 mg to about 320 mg of oxycodone hydrochloride active pharmaceutical ingredient having less than 25 ppm 14-hydroxycodeinone, wherein at least a portion of the 14-hydroxycodeinone is derived from
view more
|
Invalid
Entry 150 |
19 |
The oral dosage form of claim 3, wherein the pharmaceutically acceptable excipient comprises a sustained release carrier.
|
Invalid
Entry 150 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
An oxycodone hydrochloride active pharmaceutical ingredient having less than 25 ppm 14-hydroxycodeinone, wherein at least a portion of the 14:hydroxycodeinone is derived from 8α,14-dihydroxy-7,8-dihydrocodeinone.
|
Invalid
Entry 150 |
4 |
The oxycodone hydrochloride active pharmaceutical ingredient of claim 1 having less than 15 ppm 14-hydroxycodeinone.
|
Invalid
Entry 150 |
5 |
The oxycodone hydrochloride active pharmaceutical ingredient of claim 1 having less than 10 ppm 14-hydroxycodeinone.
|
Invalid
Entry 150 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A parenteral abuse-proofed solid dosage form for oral administration, comprising, in addition to one or more active ingredients with potential for abuse selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics,
view more
|
Invalid
Entry 164 |
2 |
A dosage form according to claim 1, wherein the active ingredient is an opiate, opioid, tranquillizer or a narcotic selected from the group consisting of
view more
|
Invalid
Entry 164 |
6 |
A dosage form according to claim 1, comprising at least one active ingredient at least partially in controlled release form.
|
Invalid
Entry 164 |
9 |
A dosage form according to claim 1, comprising the at least one viscosity-increasing agent in a quantity of ≧5 mg per administration unit.
|
Invalid
Entry 164 |
-
Infringement
Teva Pharmaceuticals USA, Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
10 mg15 mg20 mg30 mg40 mg7.5 mgOxymorphone hydrochloride extended release tablet 5 mg | US 7,776,314 B2 |
1, 2, 6, 9
|
No infringement
Entry 150
|